Ferring Pharma Announces EU Launch Of CORTIMENT®MMX® (budesonide) For Ulcerative Colitis

Ferring Pharma Announces EU Launch Of CORTIMENT®MMX® (budesonide) For Ulcerative Colitis
Ferring Pharmaceuticals recently announced the European launch of CORTIMENT® MMX® (budesonide) to address active mild and moderate ulcerative colitis (UC) -- the first and only approved oral drug for the disease. The company has also released more data concerning the CONTRIBUTE trial, which revealed that CORTIMENT®MMX® 9 mg was significantly more effective in comparison to placebo in inducing combined clinical and endoscopic remission in patients suffering from UC that continued to experience a flare up of the disease in spite of taking oral 5-ASA therapy. Data was presented at the 10th Congress of the European Crohn’s and Colitis Organisation (ECCO). David Rubin, a Professor of Medicine at the University of Chicago Medicine and lead author of the CONTRIBUTE study, said in a press release: “The data confirm the efficacy and safety of CORTIMENT®MMX® in patients experiencing an active flare of UC despite initial oral 5-ASA therapy and in a controlled setting that is consistent with clinical practice and the ECCO treatment guidelines2. CORTIMENT®MMX® is an important new option for treating active mild-to-moderate ulcerative colitis.” Ulcerative colitis is a disease that affects more than 2 million individuals in Europe. It is a chronic inflammatory disease and a life-long condition that affects both the colon and rectum. In cases in which patients are treated with oral 5-ASA and there are is no remission, patients are often treated with systemic corticosteroids that often cause side effects. CORTIMENT® MMX® is an alternative that fulfills this unmet need of oral corticosteroids that display a favorable adverse event profile. “Ulcerative colitis can be a difficult condition to manage particularly during a flare up with man
Subscribe or to access all post and page content.